Literature DB >> 7832390

Stereotactic needle biopsy for occult breast lesions: a minimally invasive alternative.

P Z Israel1, R E Fine.   

Abstract

Women are being screened with annual mammography in increasing numbers to achieve early diagnosis and improve chances of survival. A minimally invasive and cost-effective biopsy technique is needed to evaluate nonpalpable mammographically detected lesions without decreasing reliability. A technique of core biopsy with a coring needle deployed in a spring loaded gun using stereotactic localization has been developed to fulfill this need. An in-depth study of 500 consecutive stereotactic core biopsies have been analyzed and reported in this article. The study gives statistical evaluation of data and reports the breakdown of the histologic diagnosis of these cases and an analysis of detected malignancies. The study suggests that 75% of the indeterminate mammographic lesions can be judged to be benign and that no further surgery is necessary. The false negative rate is discussed in detail. The indications for stereotactic biopsy, the proper selection of patients, and the suggested follow-up are also addressed. The benign and malignant lesions are characterized in detail.

Entities:  

Mesh:

Year:  1995        PMID: 7832390

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

1.  The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions.

Authors:  A E Ibrahim; A C Bateman; J M Theaker; J L Low; B Addis; P Tidbury; C Rubin; M Briley; G T Royle
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

Review 2.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

3.  Stereotactic core-needle breast biopsy by surgeons: minimum 2-year follow-up of benign lesions.

Authors:  R P Burns; J P Brown; S M Roe; L R Sprouse; A E Yancey; L E Witherspoon
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.